Translational High‐Dimensional Drug Interaction Discovery and Validation Using Health Record Databases and Pharmacokinetics Models

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Clinical pharmacology and therapy

• Publication date

  2018-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/cpt.914PMID 29052226
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance Database

  2017cited by this paper
• Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug Interactions.

  2016cited by this paper
• Rhabdomyolysis associated with single-dose intravenous esomeprazole administration

  2016cited by this paper
• Coupling Data Mining and Laboratory Experiments to Discover Drug Interactions Causing QT Prolongation.

  2016cited by this paper
• Identification and Mechanistic Investigation of Drug–Drug Interactions Associated With Myopathy: A Translational Approach

  2015cited by this paper
• A Mixture Dose–Response Model for Identifying High-Dimensional Drug Interaction Effects on Myopathy Using Electronic Medical Record Databases

  2015cited by this paper
• Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.

  2014cited by this paper
• Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins.

  2014cited by this paper
• Literature Based Drug Interaction Prediction with Clinical Assessment Using Electronic Medical Records: Novel Myopathy Associated Drug Interactions

  2012cited by this paper
• The Need for Translational Research on Drug–Drug Interactions

  2012cited by this paper
• Data-Driven Prediction of Drug Effects and Interactions

  2012cited by this paper
• Omeprazole-induced myositis in a child receiving triple therapy for Helicobacter pylori infection.

  2012cited by this paper
• Prescription drug use continues to increase: U.S. prescription drug data for 2007-2008.

  2010cited by this paper
• Prediction of the Effect of Erythromycin, Diltiazem, and Their Metabolites, Alone and in Combination, on CYP3A4 Inhibition

  2009cited by this paper
• Predicting Drug–Drug Interactions: An FDA Perspective

  2009cited by this paper
• Semiphysiologically Based Pharmacokinetic Models for the Inhibition of Midazolam Clearance by Diltiazem and Its Major Metabolite

  2009cited by this paper
• Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.

  2008cited by this paper
• A Combined Model for Predicting CYP3A4 Clinical Net Drug-Drug Interaction Based on CYP3A4 Inhibition, Inactivation, and Induction Determined in Vitro

  2008cited by this paper
• Drug interactions and pharmacogenomics in the treatment of breast cancer and depression.

  2008cited by this paper
• Polypharmacy in elderly patients.

  2007cited by this paper
• A Novel Model for the Prediction of Drug-Drug Interactions in Humans Based on in Vitro Cytochrome P450 Phenotypic Data

  2007cited by this paper
• Simulation and prediction of in vivo drug metabolism in human populations from in vitro data

  2007cited by this paper
• Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug–drug interaction risk assessment

  2007cited by this paper
• Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?

  2006cited by this paper
• Effects of premedication medicines on the formation of the CYP3A4-dependent metabolite of ropivacaine, 2', 6'-Pipecoloxylidide, on human liver microsomes in vitro.

  2006cited by this paper
• Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.

  2005cited by this paper
• IMPACT OF PARALLEL PATHWAYS OF DRUG ELIMINATION AND MULTIPLE CYTOCHROME P450 INVOLVEMENT ON DRUG-DRUG INTERACTIONS: CYP2D6 PARADIGM

  2005cited by this paper
• Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes.

  2005cited by this paper
• Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6

  2004cited by this paper
• Database analyses for the prediction of in vivo drug-drug interactions from in vitro data.

  2004cited by this paper
• In vitro forecasting of drugs which may interfere with the biotransformation of midazolam

  2004cited by this paper
• Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.

  2004influential reference
• Pharmacokinetic and Pharmacodynamic Interactions of Oral Midazolam with Ketoconazole, Fluoxetine, Fluvoxamine, and Nefazodone

  2003cited by this paper
• Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

  2003cited by this paper
• Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide

  2003cited by this paper
• A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions

  2002cited by this paper
• Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports

  2001cited by this paper
• An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation.

  2000cited by this paper
• Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s.

  2000cited by this paper
• Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System

  1999cited by this paper
• Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential.

  1999cited by this paper
• A Bayesian neural network method for adverse drug reaction signal generation

  1998cited by this paper
• Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19.

  1996cited by this paper
• Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

  1995cited by this paper
• Case report.

  1995cited by this paper
• Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride.

  1995cited by this paper
• Autoimmune syndrome induced by omeprazole.

  1994cited by this paper
• Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.

  1994cited by this paper
• Goodman and Gilman's The Pharmacological Basis of Therapeutics

  1991cited by this paper

• Association of Omeprazole‐Related Myopathy With Drug–Drug and Drug–Gene Interactions Involving CYP2C19 and CYP3A4: A Nested Case–Control Study

  2025influential citation
• Data mining results for reduction of adverse drug–drug interaction events in older adults are clinically applicable

  2025cites this paper
• Potential Drug Dose‐Specific Adverse Three‐Drug Combinations: A US Insurance Claims Data‐Based Study

  2025cites this paper
• Proposing a framework to quantify the potential impact of pharmacokinetic drug–drug interactions caused by a new drug candidate by using real world data about the target patient population

  2024cites this paper
• Development of a Physiologically Based Pharmacokinetic Population Model for Diabetic Patients and its Application to Understand Disease-drug–drug Interactions

  2024cites this paper
• A Precision Mixture Risk Model to Identify Adverse Drug Events in Subpopulations Using a Case‐Crossover Design

  2024cites this paper
• Application of an Innovative Data Mining Approach Towards Safe Polypharmacy Practice in Older Adults

  2023cites this paper
• An optimization‐based stochastic model of the two‐compartment pharmacokinetics

  2022cites this paper
• PhenoDEF: a corpus for annotating sentences with information of phenotype definitions in biomedical literature

  2022cites this paper
• Advancement in predicting interactions between drugs used to treat psoriasis and its comorbidities by integrating molecular and clinical resources

  2021cites this paper
• A pharmacovigilance study of pharmacokinetic drug interactions using a translational informatics discovery approach

  2021cites this paper
• Antifungal Drugs TDM: Trends and Update

  2021cites this paper
• A Stochastic Analysis of the One Compartment Pharmacokinetic Model Considering Optimal Controls

  2020cites this paper
• Dual-Layer Strengthened Collaborative Topic Regression Modeling for Predicting Drug Sensitivity

  2020cites this paper
• A super‐combo‐drug test to detect adverse drug events and drug interactions from electronic health records in the era of polypharmacy

  2020cites this paper
• Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

  2020cites this paper
• Mining and visualizing high-order directional drug interaction effects using the FAERS database

  2020influential citation
• COVID-19 treatment: Combining anti-inflammatory and antiviral therapeutics using a network-based approach.

  2020cites this paper
• Applications of Data Mining in Healthcare

  2019cites this paper
• Propensity score‐adjusted three‐component mixture model for drug‐drug interaction data mining in FDA Adverse Event Reporting System

  2019cites this paper
• A Case‐Crossover–Based Screening Approach to Identifying Clinically Relevant Drug–Drug Interactions in Electronic Healthcare Data

  2019cites this paper
• Deep Learning for High-Order Drug-Drug Interaction Prediction

  2019cites this paper
• Data-driven queries between medications and spontaneous preterm birth among 2.5 million pregnancies.

  2019cites this paper
• Reverse Translational Pharmacology Research Is Driven by Big Data

  2018cites this paper
• Computational Drug Recommendation Approaches toward Safe Polypharmacy

  2018cites this paper
• Reverse Translation: The Art of Cyclical Learning

  2018cites this paper
• Drug Recommendation toward Safe Polypharmacy

  2018cites this paper
• Pattern Discovery from High-Order Drug-Drug Interaction Relations

  2018cites this paper
• A chronological pharmacovigilance network analytics approach for predicting adverse drug events

  2018cites this paper